Bukwang Pharm - Asset Resilience Ratio
Bukwang Pharm (003000) has an Asset Resilience Ratio of 39.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 003000 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how Bukwang Pharm's Asset Resilience Ratio has changed over time. See 003000 net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Bukwang Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 003000 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩188.03 Billion | 39.75% |
| Total Liquid Assets | ₩188.03 Billion | 39.75% |
Asset Resilience Insights
- Very High Liquidity: Bukwang Pharm maintains exceptional liquid asset reserves at 39.75% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Bukwang Pharm Industry Peers by Asset Resilience Ratio
Compare Bukwang Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Bukwang Pharm (2007–2024)
The table below shows the annual Asset Resilience Ratio data for Bukwang Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 10.72% | ₩40.00 Billion ≈ $27.11 Million |
₩373.18 Billion ≈ $252.90 Million |
+10.34pp |
| 2021-12-31 | 0.38% | ₩1.50 Billion ≈ $1.02 Million |
₩397.42 Billion ≈ $269.32 Million |
-2.19pp |
| 2020-12-31 | 2.57% | ₩10.30 Billion ≈ $6.98 Million |
₩400.97 Billion ≈ $271.73 Million |
-3.95pp |
| 2014-12-31 | 6.51% | ₩15.43 Billion ≈ $10.46 Million |
₩236.82 Billion ≈ $160.49 Million |
-2.28pp |
| 2013-12-31 | 8.79% | ₩20.07 Billion ≈ $13.60 Million |
₩228.21 Billion ≈ $154.66 Million |
+3.73pp |
| 2008-12-31 | 5.06% | ₩11.67 Billion ≈ $7.91 Million |
₩230.55 Billion ≈ $156.24 Million |
-8.07pp |
| 2007-12-31 | 13.13% | ₩28.24 Billion ≈ $19.14 Million |
₩215.02 Billion ≈ $145.71 Million |
-- |
About Bukwang Pharm
Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, live… Read more